title: Polyarginine and PEG-AEYLR comodified nanostructured lipid carrier: 10mol% uncleavable PEG-AEYLR showed no shielding effect to polyarginine in vitro while maintaining good tumor targeting in vivo.
abstract: We constructed a dual ligands-modified nanostructured lipid carrier (NLC) called PAR-NLC, in which the epidermal growth factor receptor (EGFR)-targeted small peptide AEYLR was attached to the distal end of PEG2000anchored on the NLC surface naming PEG-AEYLR, and poly-arginine (R8) as a classic cell-penetrating peptide was attached directly to the NLC surface. PAR-NLC was near-spherical particle with average size ∼50 nm and zeta potential at +14.09 mV; the cellular uptake of PAR-NLC showed synergistic effect of the two peptides, presented as significant superior cellular uptake in EGFR-positive cells NCI-H1299 and S180 over EGFR-negative cell K562. In the animal optical imaging study, 2 h after the administration of the Dir-loaded PAR-NLC, maximum Dir signal appeared in tumor tissue, indicating prompt tumor targeting effect, as time prolonged to 48 h, the Dir signal attenuated in the organs except tumor, suggesting constant clearance from the body. In the in vivo antitumor study, in premise of the same dose, paclitaxel-loaded PAR-NLC exhibited better antitumor and safety effect than Taxol, the body weight of the mice was more stable and tumor size was smaller. In summary, PAR-NLC was a potential drug carrier to deliver anticancer drugs safely and effectively.
authors.affiliation: a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.|b School of Pharmacy , Qiqihar Medical University , Qiqihar , China.
authors.forename: Mingshuang
authors.initials: M
authors.lastname: Sun
authors.affiliation: a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Zhu
authors.affiliation: a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
authors.forename: Huixin
authors.initials: H
authors.lastname: Wang
authors.affiliation: b School of Pharmacy , Qiqihar Medical University , Qiqihar , China.
authors.forename: Shanshan
authors.initials: S
authors.lastname: Jin
authors.affiliation: a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
authors.forename: Xinggang
authors.initials: X
authors.lastname: Yang
authors.affiliation: b School of Pharmacy , Qiqihar Medical University , Qiqihar , China.
authors.forename: Cuiyan
authors.initials: C
authors.lastname: Han
authors.affiliation: a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
authors.forename: Weisan
authors.initials: W
authors.lastname: Pan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D004337:Drug Carriers / Q000737:chemistry*; D065546:Drug Liberation; D006801:Humans; D020014:K562 Cells; D008055:Lipids / Q000737:chemistry*; D051379:Mice; D049329:Nanostructures / Q000737:chemistry*; D017239:Paclitaxel / Q000737:chemistry / Q000494:pharmacology; D010455:Peptides / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D008055:Lipids; D010455:Peptides; C015462:polyarginine; D011092:Polyethylene Glycols; D017239:Paclitaxel
keywords: Dual ligands-comodified NLC; EGFR targeting; fast tumor accumulation; tissue distribution; uncleavable PEG modification